Patents Assigned to RXi Pharmaceuticals Corporation
-
Publication number: 20170051288Abstract: Aspects of the invention relate to methods for treating cancer by administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding mouse double minute 1 homolog (MDM1), mouse double minute 2 homolog (MDM2), mouse double minute 3 homolog (MDM3), mouse double minute 4 homolog (MDM4) or V-myc myelocytomatosis viral related oncogene (MYCN) for treating cancer. Further aspects of the invention relate to nucleic acid molecules and compositions comprising nucleic acid molecules.Type: ApplicationFiled: April 28, 2015Publication date: February 23, 2017Applicant: RXi Pharmaceuticals CorporationInventors: Michael Byrne, Karen G. Bulock, James Cardia
-
Publication number: 20170009239Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.Type: ApplicationFiled: February 11, 2016Publication date: January 12, 2017Applicant: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
-
Patent number: 9493774Abstract: The invention relates to various PCSK9 RNAi constructs with gene silencing activities, and uses thereof. The construct has a double-stranded region of 19-49 nucleotides, preferably 25, 26, or 27 nucleotides, and preferably blunt-ended. The construct has selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. The sense strand may be modified such that the construct is not cleaved by Dicer or other RNAse III, and the entire length of the antisense strand is loaded into RISC. In addition, the antisense strand may also be modified by 2?-O-methyl groups at the 2nd 5?-end nucleotide to greatly reduce off-target silencing. The constructs of the invention largely avoid the interferon response and sequence-independent apoptosis in mammalian cells, exhibits better serum stability, and enhanced target specificity.Type: GrantFiled: January 5, 2010Date of Patent: November 15, 2016Assignee: RXi Pharmaceuticals CorporationInventors: Joanne Kamens, Anastasia Khvorova
-
Publication number: 20160304875Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications. Aspects of the invention provide nucleic acid molecules for the prophylactic treatment of wounding to reduce scarring. Herein, it is demonstrated that a specific nucleic acid molecule, RXI-109 (targeting connective tissue growth factor (CTGF)), given prophylactically, reduces scarring during wound healing.Type: ApplicationFiled: December 4, 2014Publication date: October 20, 2016Applicant: RXi Pharmaceuticals CorporationInventors: Gerard Cauwenbergh, Pamela A. Pavco, Lyn Libertine, Karen G. Bulock, James Cardia
-
Patent number: 9340786Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.Type: GrantFiled: March 24, 2011Date of Patent: May 17, 2016Assignee: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
-
Patent number: 9303259Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.Type: GrantFiled: December 12, 2013Date of Patent: April 5, 2016Assignee: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
-
Patent number: 9175289Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.Type: GrantFiled: May 15, 2014Date of Patent: November 3, 2015Assignee: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
-
Patent number: 9074211Abstract: RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2?-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2?-O-methyl group at the penultimate 5?-end nucleotide to greatly reduce off-target silencing.Type: GrantFiled: November 19, 2009Date of Patent: July 7, 2015Assignee: RXi Pharmaceuticals CorporationInventors: Tod M. Woolf, Joanne Kamens, Anastasia Khvorova, William Salomon
-
Publication number: 20140364482Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.Type: ApplicationFiled: May 15, 2014Publication date: December 11, 2014Applicant: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
-
Publication number: 20140315974Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.Type: ApplicationFiled: December 12, 2013Publication date: October 23, 2014Applicant: RXI PHARMACEUTICALS CORPORATIONInventors: ANASTASIA KHVOROVA, WILLIAM SALOMON, JOANNE KAMENS, DMITRY SAMARSKY, TOD M. WOOLF, PAMELA A. PAVCO, JAMES CARDIA
-
Patent number: 8815818Abstract: The present invention provides a particulate delivery system for delivering an RNAi construct to phagocytic cells such as macrophages, comprising various configurations of a complex comprising a phagocytic cell-targeting moiety and an RNAi construct. The invention further provides methods of making the delivery system, and their uses, such as treating phagocytic cell-associated disease conditions.Type: GrantFiled: July 17, 2009Date of Patent: August 26, 2014Assignee: RXi Pharmaceuticals CorporationInventors: Dmitry Samarsky, Tod M. Woolf
-
Patent number: 8796443Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.Type: GrantFiled: September 22, 2009Date of Patent: August 5, 2014Assignee: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
-
Publication number: 20140113950Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.Type: ApplicationFiled: March 24, 2011Publication date: April 24, 2014Applicant: RXI PHARMACEUTICALS CORPORATIONInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock
-
Patent number: 8664189Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.Type: GrantFiled: September 22, 2009Date of Patent: March 4, 2014Assignee: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
-
Publication number: 20120065243Abstract: The present invention relates to RNAi constructs and their use in gene silencing. RNAi constructs associated with the invention contain a double stranded region connected to a single stranded region of phosphorothioate modified nucleotides.Type: ApplicationFiled: February 4, 2010Publication date: March 15, 2012Applicant: RXi Pharmaceuticals CorporationInventors: Tod M. Woolf, Joanne Kamens, William Salomon, Anastasia Khvorova
-
Publication number: 20120059046Abstract: RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2?-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2?-O-methyl group at the penultimate 5?-end nucleotide to greatly reduce off-target silencing.Type: ApplicationFiled: November 19, 2009Publication date: March 8, 2012Applicant: RXi Pharmaceuticals CorporationInventors: Tod M Woolf, Joanne Kamens, Anastasia Khvorova, William Salomon
-
Publication number: 20120040459Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing.Type: ApplicationFiled: September 22, 2009Publication date: February 16, 2012Applicant: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
-
Publication number: 20120016005Abstract: The present invention provides a particulate delivery system for delivering an RNAi construct to phagocytic cells such as macrophages, comprising various configurations of a complex comprising a phagocytic cell-targeting moiety and an RNAi construct. The invention further provides methods of making the delivery system, and their uses, such as treating phagocytic cell-associated disease conditions.Type: ApplicationFiled: July 17, 2009Publication date: January 19, 2012Applicant: RXi Pharmaceuticals CorporationInventors: Dmitry Samarsky, Tod M. Woolf
-
Publication number: 20110263680Abstract: The present invention relates to RNAi constructs with minimal double-stranded regions, and their use in gene silencing. RNAi constructs associated with the invention include a double stranded region of 8-14 nucleotides and a variety of chemical modifications, and are highly effective in gene silencing. The RNAi constructs may be, for instance, miRNA constructs that are miRNA modulators.Type: ApplicationFiled: March 23, 2011Publication date: October 27, 2011Applicant: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
-
Publication number: 20110251258Abstract: The invention relates to improved double-stranded RNAi constructs (sometimes referred to as “solo-rxRNA”) and uses thereof. The construct comprises a structure formed in some aspects of the invention by two identical single-stranded polynucleotides, with the structure having two double-stranded stem regions (each having less than 21 base pairs) and a loop or bulge having about 4 to 11 nucleotides on each strand. The construct is resistant to cleavage by Dicer or other Dicer-like RNase III enzymes and is capable of being loaded into a RISC complex to effect RNA interference. In addition, the nucleotides of the present hairpin constructs may be modified to greatly enhance functionality, such as stability and specificity.Type: ApplicationFiled: July 23, 2009Publication date: October 13, 2011Applicant: RXi Pharmaceuticals CorporationInventors: Dmitry Samarsky, Tod M. Woolf, William Solomon, Joanne Kamens, Anastasia Khvorova, Pamela A. Pavco